What is the clinical evidence from this study?

Study design: Case Report. Population: Thyrotoxic periodic paralysis (n=1). Intervention: Potassium replacement, propranolol and antithyroid therapy. Primary outcome: Resolution of paralysis.

What does this research mean for the field?

Thyrotoxic periodic paralysis can present with severe hypokalaemia and cardiac involvement in Caucasian patients and is effectively managed with cautious potassium replacement, beta-blockers, and antithyroid therapy. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This case aims to highlight the diagnosis and management of thyrotoxic periodic paralysis (TPP) with cardiac implications due to severe hypokalaemia.

June 24, 2026BMJ Case Reports

Thyrotoxic periodic paralysis presenting with severe hypokalaemia and cardiac involvement

View Full Paper

Ask AI

Bookmark

Key result

Cautious potassium, propranolol, and antithyroid therapy resolves paralysis within 24 hours without rebound hyperkalemia.

Key Points

This case aims to highlight the diagnosis and management of thyrotoxic periodic paralysis (TPP) with cardiac implications due to severe hypokalaemia.
Emergency evaluation of a Caucasian male in his 20s with quadriparesis and hypokalaemia (1.7 mmol/L) after high-carb meal and exertion.
Thyroid function tests confirmed severe hyperthyroidism and Graves' disease as the cause.
Treatment involved potassium replacement, propranolol, and antithyroid therapy.
Paralysis resolved completely within 24 hours post-treatment without rebound hyperkalaemia.
Marked QTc prolongation was observed (594 ms) and mild troponin I elevation was noted (51 ng/L).
Following treatment, the patient maintained a euthyroid state without recurrence of symptoms.

Study Design

Type

Case Report (n=1)

Structured PICO

Population

A Caucasian man in his 20s presenting with acute flaccid quadriparesis, profound hypokalaemia, and marked QTc prolongation diagnosed with thyrotoxic periodic paralysis.

Intervention

Cautious potassium replacement, propranolol, and antithyroid therapy

This case highlights the importance of recognizing thyrotoxic periodic paralysis in individuals of any ethnic background and emphasizes cautious potassium replacement to prevent rebound hyperkalemia.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Cautious potassium replacement safely manages thyrotoxic periodic paralysis; leaves open the.

Cite This Study

Kothia et al. (2026) conducted a case report in Thyrotoxic periodic paralysis (n=1). Potassium replacement, propranolol and antithyroid therapy was evaluated on Resolution of paralysis. Treatment with cautious potassium replacement, propranolol, and antithyroid therapy led to complete resolution of paralysis within 24 hours without rebound hyperkalaemia.

synapsesocial.com/papers/6a3c2381d15afadd906fa3cd https://doi.org/10.1136/bcr-2026-272286

View Full Paper

Ask AI

Bookmark

Thyrotoxic periodic paralysis presenting with severe hypokalaemia and cardiac involvement

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Thyrotoxic periodic paralysis presenting with severe hypokalaemia and cardiac involvement

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider